Noah Weiland © 2021 The New York Times

Opinions/Stories

High hopes for Johnson & Johnson’s COVID vaccine have fizzled in the US

State officials had initially hoped the Johnson & Johnson shot would be a workhorse: a versatile, easy-to-store tool they could stockpile at mass vaccination sites.

via The New York Times
Read Article

US releases new COVID-19 guidance for nursing homes, permitting indoor visits

The recommendations, released by the Centers for Medicare and Medicaid Services with comment from the Centers for Disease Control and Prevention, are the first revision to the federal government’s…

via The New York Times
Read Article

Biden inherits a vaccine supply unlikely to grow before April

President Joe Biden’s goal of 1 million shots a day for the next 100 days, they say, is too low and will arguably leave tens of millions of doses unused

via The New York Times
Read Article

Last-minute rule seeks to impose term limits on top career health officials

Under the rule, more than a dozen senior officials could lose their positions as soon as this year — including a key regulator at the FDA responsible for evaluating COVID-19 drugs. Altogether,…

via The New York Times
Read Article

Johnson & Johnson expects vaccine results soon but lags in production

Unlike those products, which require two doses, Johnson & Johnson’s could need just one, greatly simplifying logistics for local health departments

via The New York Times
Read Article

Trump administration passed on chance to secure more of Pfizer vaccine

President Donald Trump has hailed the development of the vaccine as a victory for his administration, even though Pfizer, unlike the developer of the other most promising vaccine, Moderna, took no…

via The New York Times
Read Article